پھیپھڑوں کا کینسر (نان سمال سیل)
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
کہاں جانا ہے
اس ٹرائل کے لیے انڈیا میں 13 ہسپتال مریضوں کو لے رہے ہیں۔
رجسٹری کی سمری (ٹیکنیکل)
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment. The Phase 3 portion of the study compares the efficacy of adagrasib in combination with pembrolizumab versus pembrolizumab in patients with unresectable, locally advanced or metastatic squamous or nonsquamous NSCLC with KRAS G12C mutation and PD-L1 TPS \>=50% and who are candidates for first line treatment.
Sponsor: Mirati Therapeutics Inc.
ClinicalTrials.gov پر NCT04613596
رجسٹری پر آخری اپڈیٹ 13 Oct 2026 · ہم نے 20 Oct 2026 کو پڑھا